文献速递肿瘤 PET/CT核素与放射性配体治疗

转移性前列腺小细胞癌中18F-FDG与18F-氟昔洛韦PET显像病灶不匹配一例

Mismatched Lesions on 18F-FDG PET and 18F-Fluciclovine PET Images in a Patient With Metastatic Prostate Small Cell Carcinoma.
PubMed 文献 · Clin Nucl Med · 2022-01-01

65岁男性转移性前列腺小细胞癌患者,诊断时PSA 19.4 ng/mL,经系统治疗和手术后达激素反应,PSA<0.1 ng/mL。术后3个月18F-氟昔洛韦PET/CT阴性;6周后因CEA升高行18F-FDG PET/CT,显示前列腺床、肝及右髂骨多发高代谢病灶,前列腺床FDG高摄取病灶经MRI证实。本例提示FDG PET/CT在氟昔洛韦PET阴性而怀疑转移性前列腺小细胞癌时有作用。

要点

  • 前列腺小细胞癌可表现为氟昔洛韦PET阴性而FDG PET阳性。
  • PSA<0.1 ng/mL时CEA升高可提示需行FDG PET/CT评估。
  • FDG高摄取的前列腺床病灶需结合MRI进一步确认。

核心结论

  • FDG PET/CT在氟昔洛韦PET阴性的疑似转移性前列腺小细胞癌中有应用价值。

研究设计与样本

  • 单例病例报告:65岁男性转移性前列腺小细胞癌患者,诊断时PSA 19.4 ng/mL,接受系统治疗及手术。

主要发现

  • 术后3个月18F-氟昔洛韦PET/CT未见疾病,PSA<0.1 ng/mL。
  • 6周后因CEA升高行18F-FDG PET/CT,显示前列腺床、肝和右髂骨多发高代谢病灶。
  • FDG高摄取的前列腺床病灶经MRI进一步确认。

临床怎么用

  • 对氟昔洛韦PET阴性但临床怀疑转移性前列腺小细胞癌者,可考虑FDG PET/CT。
  • PSA<0.1 ng/mL而CEA升高时,应警惕不依赖PSA的病灶并进一步影像评估。

局限性

  • 仅为单例病例报告,结论外推需谨慎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

A 65-year-old man with fluciclovine-avid metastatic prostate small cell carcinoma with prostate-specific antigen (PSA) 19.4 ng/mL at diagnosis underwent system therapy and subsequent surgery and achieved hormonal response with PSA <0.1 ng/mL. An 18F-fluciclovine PET/CT scan 3 months after surgery was negative for disease. Although PSA remained <0.1 ng/mL, the rising carcinoembryonic antigen prompted an 18F-FDG PET/CT 6 weeks later. It showed multiple hypermetabolic lesions in the prostatectomy bed, liver, and right iliac bone, suggestive of malignant disease. The FDG-avid prostatectomy lesions were further confirmed on MRI. This case demonstrates that FDG PET/CT has a role in suspected metastatic prostate small cell carcinoma with negative fluciclovine PET examination.

来源:Clin Nucl Med,查看原文。版权归原作者所有。

引用

  1. Gu J, Lu Y, Xu G, et al. Mismatched Lesions on 18F-FDG PET and 18F-Fluciclovine PET Images in a Patient With Metastatic Prostate Small Cell Carcinoma. Clin Nucl Med. 2022. PMID: 34392287. doi:10.1097/RLU.0000000000003864

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。